NCT07111299Active, not recruitingNot Applicable
Clinical Evaluation of Hair Loss, Hair Growth, and Skin Improvement in Human Volunteers Following a Double-blind, Placebo-controlled, 1:1 Randomized Trial of 'Olistic Next Women'
Olistic Research Labs S.L.1 site in 1 country100 target enrollmentStarted: October 13, 2025Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 100
- Locations
- 1
- Primary Endpoint
- Increase in hair density
Study Overview
Brief Summary
The purpose of this clinical trial is to evaluate the efficacy and safety of Olistic Next Women, a nutraceutical supplement, in women experiencing beginning of FPHL.
This 6-month, double-blind, placebo-controlled, 1:1 randomized clinical trial investigates whether daily supplementation with Olistic Women or Olistic Next Women leads to significant improvements in hair parameters compared to placebo. The study also monitors the tolerability and safety of the product throughout the intervention.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Care Provider, Investigator)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- Female
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Women aged 18-
- •Volunteers with initial FPHL. (Images will be sent to a dermatologist for assessment).
- •Commitment not to use systemic, topical, or oral products with an effect similar to that of the product to be evaluated throughout the study period.
- •Do not change the daily routine regarding the use of cosmetic products and eating habits.
- •Commitment to comply with all protocol requirements specified in the subject information sheet.
- •Availability to comply with all study visits.
Exclusion Criteria
- •Allergy or reactivity to some of the components of the product, or a product with similar category than tested one.
- •Women who have undergone dermatological treatment for hair loss (PRPs, mesotherapy, etc.) or hair transplant.
- •Scalp diseases: cicatricial alopecia, alopecia areata, folliculitis decalvans, psoriasis, moderate severe seborrheic dermatitis, eczema, cancer, etc.
- •Women who present alopecia because of a medical illness (hypothyroidism, anemia, lupus, etc.).
- •Relevant cutaneous marks in the experimental areas, which could interfere with the measurements (scars, sunburns, etc.).
- •In-use relevant pharmacological or hormonal treatment (eg. valproic acid, carbamazepine, phenytoin).
- •Women with thyroid alteration (hyper- or hypothyroidism)
- •Women who have previously participated in similar studies or who have used anti-hair loss products in the last 3 months.
- •Women who are being treated with anticoagulants, antifungals, anxiolytics, amphetamines, retinoids, iron, antithyroid, anticonvulsants, beta blockers and/or ACE inhibitors, minoxidil, finasteride, etc.
- •Women who started hormonal treatment (oral or topical contraceptives) in the 6 months prior to the start of the study.
- •Women who started taking any drug chronically less than 6 months before the start of the study (they should have a stable situation with the medication over 6 months).
- •Modification of the usual diet: low-calorie diet, Atkins diet, etc.
- •Pregnant, postpartum (6 months) or breastfeeding women, or who intend to get pregnant during the duration of the study.
- •Evidence of systemic diseases (e.g. cardiac disease, psychiatric disease, etc.) or gastrointestinal diseases.
- •Serious conditions or illnesses that, in the opinion of the researcher, may be aggravated by participation in the study or that put the development of the study at risk.
- •Planned hairstyle changes throughout the study
- •Presence of skin diseases or melanomas.
- •Forecast of change of routine or relevant way of life, during the period of study.
- •Other exclusion criteria to be added by the customer.
- •Women who have gone dermatological treatment, that they have introduced minoxidil (oral or topical) at least 6 months prior, and antiandrogens (e.g. finasteride) at least 12 months before the start of the study.
Arms & Interventions
Placebo Arm - Olistic Next Women
Placebo Comparator
Intervention: Placebo Control (Other)
Active Product Arm - Olistic Women
Experimental
Intervention: Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women 18-35 years. (Dietary Supplement)
Placebo Arm - Olistic Women
Placebo Comparator
Intervention: Placebo Control (Other)
Active Product Arm - Olistic Next Women
Experimental
Intervention: Drinkable multifactorial food supplement containing vitamins, minerals, plant extracts, and other bioactive compounds, formulated to support hair growth and scalp health in women over 35 years. (Dietary Supplement)
Outcomes
Primary Outcomes
Increase in hair density
Time Frame: From enrollment to the end of treatment at 180 days.
From phototrichogram on the Sagittal midline area of the scalp
Secondary Outcomes
- Change in hair shedding(From enrollment to the end of treatment at 180 days.)
- Change in hair shedding(From enrollment to the end of treatment at 180 days.)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Not Applicable
Clinical Test Report for improving hair loss of 2 CosmeticsDiseases of the skin and subcutaneous tissueKCT0005501Seowon University48
Completed
Phase 2
Study of effectiveness and safety on the hair loss restraint by scalp cooling with scalp cooling device in the breast cancer chemotherapyBreast cancerJPRN-UMIN000031534ational Hospital Organization Kyushu Cancer Center120
Suspended
Phase 2
Hair loss restraint by scalp cooling enforcementBreast cancerJPRN-jRCTs072180051TOKUNAGA Eriko21
Recruiting
Not Applicable
Dermoscopy of scalp and hair disordersCTRI/2018/05/014206Government Medical College
Recruiting
Unknown
Observational study on hair regrowth in patients with chemotherapy-induced alopeciaCancerJPRN-UMIN000051431Oita University100